Research

Scientific studies pointing to potential health effects of the various beta casein types have generated wide international interest and research is ongoing as to how the beta casein variants can affect our health.
 
A summary of research behind beta casein “Beta casein A1 and A2 in milk and human health” concluded:

 
Key research including population, human and animal studies can be found referenced below.
 
 
Childhood (Type 1) Diabetes
Epidemiological (Population) studies
Drinking milk high in A2 beta casein at 2 yrs of age was linked to a lower risk of childhood diabetes in Iceland and Scandinavia. Drinking milk containing A1 casein in early childhood was linked with diabetes.
Drinking milk high in A2 beta casein is linked to a lower risk of childhood diabetes in Icelandic children.
The low rate of diabetes in Iceland was linked to their milk containing less A1 beta casein compared to other Nordic countries showing that lower consumption of A1 decreases rates of diabetes.
Across 20 countries beta casein A1 consumption is shown to be strongly associated with rates of diabetes concluding that milk high in A2 beta casein may lower the risk of childhood diabetes.
Drinking milk high in A2 beta casein in childhood may lower the risk of childhood diabetes.
Drinking milk higher in beta casein A1 is strongly linked to the rate of childhood diabetes in 0-14 year olds.
Low amounts of A1 beta casein in Icelandic cows’ milk is linked to the lower childhood diabetes rate in Iceland compared to the rest of Scandinavia.
A strong link was shown between A1 beta casein and the rate of childhood diabetes across different German states. This shows that higher A1 consumption is linked to increased rates of childhood diabetes.
b-casein A1 consumption and incidence of Type 1 Diabetes in Germany.
Wasmuth, H.E., Rosenbauer, J., Elliott, RB., Mclachlan, C., Erhardt, G., Giani, G., Kolb, H.: Kongress der Europäischen Diabetesgesellschaft vom 28.-30.09.1999 in Brüssel/Belgien (Conference Presentation)
A1 beta casein is linked to the rate of childhood diabetes, but A2 is not.
The consumption of A1 beta casein was found to correspond with the rate of childhood diabetes in children age 0-14 years, showing a linkage between A1 consumption and rate of childhood diabetes
Human studies
Antibodies to A1 beta casein were detected in type 1 diabetes patients whereas antibodies to A2 beta casein were present in ‘control’ patients. This supports the link between A1 consumption and childhood diabetes
High levels of antibodies to beta casein were found in the blood of patients with childhood diabetes, adult latent autoimmune diabetes and coeliac disease linking beta casein to these diseases
Breast feeding for the first 4 months was shown to prevent antibody (immune) response to cow beta casein (linked to childhood diabetes)
Those with childhood diabetes had an immune response towards beta casein. This is evidence that beta casein could be a environmental trigger for genetically susceptible individuals to develop childhood diabetes.
Other research
BCM7 was linked to childhood diabetes
The role of ß-casein variants in the induction of insulin-dependent diabetes in the non-obese diabetic mouse and humans.
Elliott RB, Wasmuth HE, Bibby NJ, Hill JP: Seminar on milk protein polymorphism, IDF special issue no. 9702. International Dairy Federation, Brussels, 445–453, 1997
Beta casomorphins affect the function of the pancreas, the site of insulin production
Influence of b-casomorphins on the function of the endocrine pancreas: ß-Casomorphins and Related Peptides: Recent Developments. Zuhlke H. Damert A. Eckhardt W. Hubner G. Kauschke R. Salazar R. Neubert K. (Brantl V. and Teschemacher H., eds.) VCH, Weinheim, 1994,, p161-169.
 

 Heart disease and cardiovascular disease
Epidemiological (population) studies
Countries that have more A1 beta casein in their milk have a higher risk of heart disease.
Data from 20 countries show that A1 beta casein consumption increased Heart Disease rates
Animal feeding studies
Animals fed more A2 beta casein than A1 had fewer signs of cardiovascular damage. A2 fed animals showed no damage to arteries and reduced damage even after cholesterol intake.
Human studies
Infant formula containing cow milk beta caseins is linked to higher levels of antibodies to oxidised LDL in infants, which shows that these infants have been exposed to biofactors linked to heart disease.
 
BCM-7 from A1 beta casein has been shown to oxidise LDL, which is strongly linked to heart disease.
 
 
Other studies
Bioactive components of milk including beta casein peptides that have positive cardiovascular effects.
 
 
BCM-7 (from bovine A1 beta casein) promotes the oxidation of human low density lipoprotein (LDL) linking bovine A1 beta casein with an increased risk of Heart Disease

Beta casein peptides linked to the symptoms of neurological conditions 
Human studies
Milk containing A2 beta casein was found not to aggravate neurological disorders
Beta casomorphins found in the urine of autistic children are linked to the aggravation of the symptoms of Autistic Spectrum Disorders (ASD)
A1 beta casein peptide BCM7 can cross the blood brain barrier and affect brain regions shown to alter in schizophrenic and autistic patients.
 
A gluten and casein free diet improved most behaviours in autistics and reduced symptoms in schizophrenic patients. Reduced levels of BCM-7 (from A1 beta casein) corresponded to improvements in symptoms.
A gluten and casein free diet resulted in a significant reduction of symptoms in autistic children linking gluten and casein consumption in the symptoms associated with autistic spectrum disorders
 

 Beta casein variants
Human studies
A1 and A2 beta casein are found in Holstein cattle. A quarter of Holsteins have only A1 genes, a quarter have only A2 genes and a half have 1 A1 and 1 A2 gene.
 
 
Dairy milk contains a balance of a1 and a2 beta casein on average
 
 
A2 beta casein is the original form of beta casein.
A1 beta casein has evolved more recently.
 
A1 beta casein is more common in more modern cattle breeds.
A2 beta casein is the original form of beta casein from which all the other beta casein types evolved.

 Bioactive digestion products of beta casein variants
BCM-7 is uniquely released from A1 variant of bovine beta casein
Comprehensive reviews of the bioactivity and physiological function of milk protein fragments including beta-casomorphins (BCMs)
 
 
 
 
 
Identification of Peptides Derived from B-casein Hydrolysates by Proteolytic Enzymes.
Park, S. Y. Gibbs B. F. Lee B. H. 1996. Korean J. Dairy Sci. 18 (4):237-246. (Korean)
Peptides from Beta Casein including the BCMs have been shown to affect gut processes
 
 
 
 
 
 
Claustre J, Toumi F, Trompette A, Jourdan G, Guignard H, Chayvialle JA, Plaisancie P. 2002. Am J Physiol Gastrointest Liver Physiol Sep;283(3):G521-8.
 

 
 Beta casomorphins (BCMs)
BCM-7 is uniquely released from A1 variant of bovine beta casein
BCM-7 was found in the guts of human subjects after they drank cows milk.
BCM7 is resistant to break down.
BCMs detected in the blood and central nervous system (CNS) of humans and animals
 
Micropurification and amino acid sequence of beta-casomorphin-8 in milk from a woman with postpartum psychosis. Renlund S, Erlandsson I, Hellman U, Silberring J, Wernstedt C, Lindstrom L, Nyberg F. 1993. Peptides.14(6):1125-32
 
Demonstration of a beta-casomorphin immunoreactive material in the plasma of newborn calves after milk intake Umbach M, Teschemacher H, Praetorius K, Hirschhauser R, Bostedt H. 1985. Regul Pept. Nov 7;12(3):223- 30.
 
Pasi A, Mahler H, Lansel N, Bernasconi C, Messiha FS.1993 Res Commun Chem Pathol Pharmacol. 80(3):305-22.
BCMs shown to have strong opioid activity
 
 
 
 
Dubynin VA, Malinovskaya IV, Ivleva YA, Andreeva LA, Kamenskii AA, Ashmarin, IP 2000. . Bull. Exp. Biol. Med. 130(11), pp1031-1034.
Beta casein peptides and BCMs found to affect the human immune system
 
 
A naturally occurring opioid peptide from cow's milk, beta-casomorphine-7, is a direct histamine releaser in man Kurek M, Przybilla B, Hermann K, Ring J. 1992.. Int Arch Allergy Immunol. 97(2):115-20.